Utang jangka cendhak marang ekuitas Revolution Medicines Inc (RVMD)

Logo grafis revmed.com (RVMD)

Serving as the primary valuation tool, this Revolution Medicines (RVMD) price chart on GURU.Markets illustrates the price action of an asset valued at 0.00. The business relies on costly research and development and patent protection, which require massive investments. Revolution Medicines (RVMD) is implementing digital bioscreening to accelerate drug discovery, while its current focus remains on creating breakthrough RAS(ON) inhibitors to combat tumors.

RVMD - Rasio utang jangka cendhak marang ekuitas Revolution Medicines Inc ing rentang 04.07.2022 - 31.10.2026
Produk mawa merek Revolution Medicines Inc

Low values of this multiple confirm high financial stability and the minimization of default risks, which is critical for long-term investment attractiveness. By analyzing the change in short-term debt relative to equity, an investor assesses the ability of Revolution Medicines (RVMD) to cover current liabilities using assets, ensuring the resources necessary for the joint development of innovative oncology drugs with global pharma behemoths.

Pesaing Revolution Medicines

Utang jangka cendhak marang modal ONC|Utang jangka cendhak marang modal Halozyme Corp (HALO)|Utang jangka cendhak marang ekuitas Ascentage Pharma Group AAPG|CGON: Rasio utang jangka cendhak marang modal|UroGen Pharma - Utang jangka cendhak marang modal|Bicara Therapeutics Inc (BCAX) - Rasio utang jangka cendhak marang ekuitas|PSNL: Utang jangka cendhak marang modal|Kewajiban jangka cendhak marang modal Erasca Oncology (ERAS)|Utang jangka cendhak marang ekuitas Delcath Systems, Inc.|YMAB: Rasio tanggungan utang jangka cendhak marang modal|Rasio utang jangka cendhak marang ekuitas AURA (Aura Biosciences)|CADL (candeltx.com) - Rasio tanggungan utang jangka cendhak marang modal|Utang jangka cendhak marang modal ARAY (Accuray Inc.)|SLS - Rasio utang jangka cendhak marang ekuitas|ACTU: Rasio utang jangka cendhak marang ekuitas|CTOR - Utang jangka cendhak marang modal|tuhurabio.com (HURA) - Utang jangka cendhak marang ekuitas|Protara Therapeutics Inc - Rasio tanggungan utang jangka cendhak marang modal|FATE (Fate Therapeutics Corp) - Utang jangka cendhak marang modal|Kewajiban jangka cendhak marang modal Aadi Bio WHWK|Utang jangka cendhak marang ekuitas TScan Therapeutics (TCRX)|CSBR (championsoncology.com) - Rasio tanggungan utang jangka cendhak marang modal|Utang jangka cendhak marang modal XBIT (XBiotech)|CEL-SCI Corp. (CVM) - Kewajiban jangka cendhak marang modal|OSTX: Rasio utang jangka cendhak marang ekuitas|RADX: Utang jangka cendhak marang ekuitas|artivabio.com (ARTV) - Utang jangka cendhak marang ekuitas|Kewajiban jangka cendhak marang modal Adlai Nortye (ANL)|Utang jangka cendhak marang ekuitas Veru|Utang jangka cendhak marang ekuitas TPST|Rasio utang jangka cendhak marang ekuitas XLO (Xilio Therapeutics, Inc.)|Utang jangka cendhak marang modal renovarobio.com (RENB)|Mural Oncology - Rasio utang jangka cendhak marang ekuitas|Rasio silihan jangka cendhak marang modal KAPA (Kairos Pharma Limited)|OnKure - Utang jangka cendhak marang modal|Koefisien utang jangka cendhak marang modal CytoMed Therapeutics GDTC|curis.com (CRIS) - Utang jangka cendhak marang ekuitas|Kewajiban jangka cendhak marang modal Apollomics (APLM)|Utang jangka cendhak marang ekuitas Tharimmune, Inc.|Rasio utang jangka cendhak marang modal ADVB (Advanced Biomed Corp)|Rasio utang jangka cendhak marang ekuitas GNPX (Genprex)|CLDI (calidibio.com) - Rasio tanggungan utang jangka cendhak marang modal|Utang jangka cendhak marang ekuitas Sunshine Biopharma SBFM|XBIO - Rasio utang jangka cendhak marang ekuitas|Salarius Pharmaceuticals - Utang jangka cendhak marang modal|Kewajiban jangka cendhak marang modal purple-biotech.com|AONC: Utang jangka cendhak marang modal|Rasio utang jangka cendhak marang modal BGNE|CKPT (Checkpoint Therapeutics, Inc) - Utang jangka cendhak marang modal|Elevation Oncology Inc. (ELEV) - Koefisien utang jangka cendhak marang modal|Utang jangka cendhak marang modal ICAD|Rasio utang jangka cendhak marang ekuitas ikenaoncology.com IKNA|Utang jangka cendhak marang modal NTBL (Notable Labs)|Koefisien utang jangka cendhak marang modal Viracta Therapeutics Inc. (VIRX)|MOR - Utang jangka cendhak marang ekuitas|NAYA (NAYA Biosciences Corp) - Rasio utang jangka cendhak marang modal|AAPGV: Utang jangka cendhak marang modal